

Paracetamol-Induced Toxicity: A Review of the Side Effects Associated with Excessive Consumption and Mishandling

Kumari Shiwani Shivam¹, Divyansh Kumar Gourav¹, Manish Kumar¹, Satyam Kumar Prajapati¹, Gourav Nag¹, Adarsh Verma¹, Mithun Kumar¹, Laxmi Kumari¹, Shridhar Minz¹, Jitendra Kumar Yadav¹, Tamanna Kumari¹, Manish Kumar Singh¹, Puja Kumari¹, Praveen Kumar Gupta¹, Kajal Kumari¹, Arnab Roy*²

¹Ranchi College of Pharmacy, Ranchi, Jharkhand-834003, India.

²Research Scholar, Kalinga University, Raipur, Chattishgarh-492001, India

ABSTRACT

Paracetamol (acetaminophen) is one of the most widely used analgesic and antipyretic medications globally, available over-the-counter in numerous formulations. Despite its perceived safety profile when used appropriately, paracetamol represents a significant cause of drug-induced liver injury and acute hepatic failure worldwide. This comprehensive review examines the mechanisms underlying paracetamol toxicity, explores the spectrum of adverse effects associated with excessive consumption and mishandling, and discusses current management strategies. The hepatotoxic potential of paracetamol is primarily mediated through the formation of the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI), which depletes glutathione stores and causes oxidative stress when the drug's normal metabolic pathways become saturated. Beyond hepatotoxicity, paracetamol overdose can result in nephrotoxicity, cardio toxicity, and metabolic acidosis. Risk factors for toxicity include chronic alcohol consumption, malnutrition, concurrent medication use, and genetic polymorphisms affecting drug metabolism. Early recognition and prompt treatment with N-acetylcysteine remain crucial for preventing irreversible organ damage. This review synthesizes current understanding of paracetamol toxicity mechanisms, clinical manifestations, risk factors, and therapeutic interventions to provide healthcare professionals with essential knowledge for managing this common yet potentially fatal poisoning.

Keywords: paracetamol, acetaminophen, hepatotoxicity, drug-induced liver injury, NAPQI, N-acetylcysteine

INTRODUCTION

Paracetamol, known as acetaminophen in North America, stands as one of the most commonly consumed pharmaceutical agents worldwide, with billions of doses consumed annually for pain relief and fever reduction. *Larson et al. (2005)* demonstrated that paracetamol-induced liver injury accounts for approximately 50% of acute liver failure cases in the United States. The drug's widespread availability, often in combination formulations, has inadvertently contributed to its potential for misuse and accidental overdose. *Blieden et al. (2014)* reported that many consumers remain unaware of

paracetamol's presence in multiple over-the-counter and prescription medications, leading to unintentional therapeutic duplication and subsequent toxicity. The therapeutic window between effective analgesia and potential toxicity is narrower than commonly perceived, particularly in vulnerable populations. *Mazaleuskaya et al. (2015)* highlighted that individual variations in metabolism, pre-existing liver disease, and concurrent medications can significantly alter paracetamol's safety profile. Understanding the mechanisms, manifestations, and management of paracetamol toxicity is crucial for healthcare providers, given the drug's ubiquitous presence in clinical practice and domestic medicine cabinets.

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.





Fig.1. Paracetamol Tablets

Source: <https://www.tradeindia.com/products/paracetamol-tablet-c7365208.html>




Fig.2. Chemical Structure of Paracetamol

1. Mechanisms of Paracetamol Toxicity

2.1. Normal Metabolic Pathways

Under therapeutic dosing conditions, paracetamol undergoes hepatic metabolism through three primary pathways. Approximately 90-95% of the drug is metabolized through conjugation reactions involving glucuronidation and sulfation, producing non-toxic metabolites that are readily excreted in urine. *Prescott (2000)* established that these conjugation pathways have high capacity but limited substrate affinity, making them the predominant routes of elimination at therapeutic doses. The remaining 5-10% of paracetamol is oxidized by the cytochrome P450 enzyme system, primarily CYP2E1 and CYP1A2, to form the reactive intermediate N-acetyl-p-benzoquinone imine (NAPQI). Under normal circumstances, NAPQI is rapidly detoxified through conjugation with glutathione, catalyzed by glutathione S-transferases. *Mitchell et al. (1973)* first identified this pathway as the critical determinant of paracetamol safety, demonstrating that glutathione depletion precedes hepatocellular necrosis. The balance between NAPQI formation and glutathione-mediated detoxification represents the fundamental

mechanism determining whether paracetamol exposure results in therapeutic benefit or toxicity.

1.2. Toxicity Mechanisms

When paracetamol intake exceeds approximately 10-15 grams in adults, or when repeated supratherapeutic doses deplete hepatic glutathione stores, the normal detoxification pathways become overwhelmed. *Jaeschke and Bajt (2006)* described how NAPQI accumulation leads to covalent binding with cellular proteins, particularly in hepatocytes, initiating a cascade of oxidative stress and cellular dysfunction. The depletion of glutathione stores, typically occurring when levels fall below 70% of normal, renders cells vulnerable to oxidative damage and lipid peroxidation. The hepatocellular injury progresses through several phases, beginning with mitochondrial dysfunction and progressing to cellular necrosis. *McGill et al. (2012)* elucidated the role of mitochondrial permeability transition pore opening in mediating paracetamol-induced hepatocyte death. This process involves calcium dysregulation, ATP depletion, and the generation of reactive oxygen species, ultimately culminating in necrotic cell death predominantly in the centrilobular regions of the liver.




Fig.3. Mechanisms of Paracetamol Toxicity

Source: <https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/paracetamol-toxicity>

2. Clinical Manifestations of Paracetamol Toxicity

3.1. Phases of Toxicity

Paracetamol poisoning typically manifests in four distinct clinical phases, each characterized by specific symptoms and biochemical changes. The initial phase, occurring within 0.5-24 hours post-ingestion, is often asymptomatic or presents with non-specific symptoms including nausea, vomiting, diaphoresis, and pallor. **Rumack and Matthew (1975)** noted that the absence of symptoms during this critical period often delays recognition and treatment, despite this being the optimal window for therapeutic intervention. The second phase, occurring 18-72 hours post-ingestion, marks the onset of hepatic injury with rising aminotransferase levels and the development of right upper quadrant pain. **Rowden et al. (2013)** emphasized that patients may experience a deceptive period of clinical improvement during the transition between phases one and two. The third phase, occurring 72-96 hours post-ingestion, represents the peak of hepatotoxicity with maximal elevation of liver enzymes, coagulopathy, and potential progression to acute hepatic failure.

2.2. Hepatotoxicity

Hepatotoxicity remains the most significant and well-characterized consequence of paracetamol toxicity. The liver injury typically manifests as acute hepatocellular necrosis, predominantly affecting zone 3 (centrilobular) hepatocytes where CYP2E1 expression is highest. **Lee (2017)** described the characteristic laboratory findings including marked elevation of aminotransferases (often exceeding 10,000 IU/L), elevated bilirubin, and prolonged prothrombin time reflecting impaired synthetic function. The severity of hepatotoxicity correlates with the magnitude of paracetamol exposure and the timing of intervention. **Khandelwal et al. (2011)** demonstrated that patients developing acute liver failure following paracetamol overdose exhibit a characteristic pattern of very high aminotransferases with relatively modest elevations in alkaline phosphatase, distinguishing it from other causes of acute hepatitis. In severe cases, hepatic encephalopathy, cerebral edema, and multi-organ failure may develop, necessitating consideration for emergency liver transplantation.

2.3. Extrahepatic Toxicity

While hepatotoxicity dominates the clinical picture, paracetamol can cause significant injury to other organ systems. Acute kidney injury occurs in 10-25% of patients with paracetamol poisoning, often in the

absence of hepatic failure. *Mazer and Perrone (2008)* identified direct nephrotoxicity through similar mechanisms involving reactive metabolite formation and oxidative stress within renal tubular cells. The kidneys contain CYP2E1 and other enzymes capable of metabolizing paracetamol to NAPQI, making them susceptible to direct toxicity. Cardiotoxicity, while less common, represents another serious extrahepatic complication of paracetamol overdose. *Shah and Eddleston (2015)* reported cases of myocardial injury, arrhythmias, and cardiovascular collapse in severe poisoning cases. The mechanisms underlying cardiotoxicity appear similar to those causing hepatic injury, involving oxidative stress and mitochondrial dysfunction within cardiomyocytes.

3. Risk Factors for Paracetamol Toxicity

4.1. Individual Susceptibility Factors

Several patient-specific factors significantly influence susceptibility to paracetamol toxicity. Chronic alcohol consumption represents one of the most important risk factors, with regular alcohol intake increasing the risk of hepatotoxicity even at therapeutic paracetamol doses. *Zimmerman and Maddrey (1995)* demonstrated that chronic alcohol use induces CYP2E1, increasing NAPQI formation while simultaneously depleting glutathione stores through chronic oxidative stress. This dual mechanism creates a scenario where even modest paracetamol intake can result in significant toxicity. Malnutrition and fasting states also predispose individuals to enhanced paracetamol toxicity through glutathione depletion. *Whitcomb and Block (1994)* showed that patients with poor nutritional status, eating disorders, or prolonged fasting have reduced hepatic glutathione reserves, making them more vulnerable to NAPQI-mediated injury. Advanced age may also increase susceptibility due to age-related decline in liver function and glutathione synthesis capacity.

3.2. Genetic Polymorphisms

Genetic variations in drug-metabolizing enzymes significantly influence individual responses to paracetamol exposure. Polymorphisms in CYP2E1, CYP1A2, and glutathione S-transferase genes can alter the balance between toxification and

detoxification pathways. *Court et al. (2001)* identified genetic variants that affect glucuronidation capacity, potentially redirecting more paracetamol toward the CYP-mediated pathway and increasing NAPQI formation. Variations in genes encoding antioxidant enzymes and glutathione synthesis also influence toxicity risk. *Posadas et al. (2010)* demonstrated that polymorphisms in glutamate-cysteine ligase, the rate-limiting enzyme in glutathione synthesis, can affect cellular defense against oxidative stress. These genetic factors may explain why some individuals develop toxicity at lower doses while others tolerate higher exposures without apparent harm.

3.3. Drug Interactions

Concurrent medications can significantly modify paracetamol toxicity risk through various mechanisms. Drugs that induce CYP enzymes, particularly CYP2E1, increase NAPQI formation and enhance toxicity potential. *Prescott (2000)* identified several medications including phenytoin, carbamazepine, and rifampin as potential enhancers of paracetamol toxicity through enzyme induction. Conversely, drugs that inhibit CYP enzymes may provide some protection by reducing NAPQI formation. Medications that deplete glutathione or interfere with its synthesis can also increase toxicity risk. *James et al. (2003)* demonstrated that certain antibiotics, particularly those affecting folate metabolism, can impair glutathione synthesis and increase susceptibility to paracetamol-induced liver injury. The timing of co-administered medications relative to paracetamol exposure is crucial in determining the magnitude of interaction effects.

4. Diagnostic Approaches

5.1. Laboratory Assessment

Early and accurate diagnosis of paracetamol toxicity relies heavily on laboratory assessment, with serum paracetamol concentrations serving as the primary diagnostic tool. The Rumack-Matthew nomogram, developed in 1975 and subsequently modified, provides a framework for assessing toxicity risk based on serum paracetamol levels and time since ingestion. *Smilkstein et al. (1988)* validated this approach and demonstrated its utility in guiding treatment decisions, though its applicability is limited to single

acute ingestions with known timing. Laboratory monitoring should include serial assessment of liver function tests, coagulation parameters, and renal function. *Bateman et al. (2014)* emphasized the importance of measuring aminotransferases (ALT and AST), bilirubin, international normalized ratio (INR), and creatinine at presentation and during follow-up. The pattern of laboratory abnormalities can help distinguish paracetamol toxicity from other causes of acute liver injury and guide management decisions.

4.2. Limitations and Challenges

Several factors complicate the diagnostic assessment of paracetamol toxicity. Staggered overdoses, where multiple supratherapeutic doses are taken over several

hours or days, present particular challenges as the standard nomogram cannot be applied. *Daly et al. (2008)* demonstrated that staggered overdoses are associated with increased morbidity and mortality, partly due to delayed recognition and treatment. In these cases, any detectable paracetamol level should be considered potentially toxic. The presence of combination products containing paracetamol can complicate both assessment and management. *Herndon et al. (2009)* noted that patients may be unaware of paracetamol content in their medications, leading to unintentional overdose and delayed recognition of toxicity. Healthcare providers must maintain high clinical suspicion and systematically review all medications when evaluating patients with unexplained liver injury.

Table 1. Clinical and Biochemical Manifestations, Risk Factors, and Diagnostic Strategies in Paracetamol Toxicity

Section	Subsection	Key Characteristics / Manifestations	Key References
3. Clinical Manifestations	3.1. Phases of Toxicity	Phase I (0.5–24 hrs): Often asymptomatic or presents with nausea, vomiting, diaphoresis, pallor. Phase II (18–72 hrs): Onset of hepatotoxicity; RUQ pain, elevated AST/ALT. Phase III (72–96 hrs): Peak hepatotoxicity; coagulopathy, encephalopathy, liver failure.	Rumack & Matthew, 1975; Rowden et al., 2013
	3.2. Hepatotoxicity	Acute centrilobular necrosis (zone 3), marked aminotransferase elevation (>10,000 IU/L), hyperbilirubinemia, prolonged PT/INR, hepatic encephalopathy.	Lee, 2017; Khandelwal et al., 2011
	3.3. Extrahepatic Toxicity	Renal: AKI (10–25% cases); direct nephrotoxicity via NAPQI. Cardiac: Rare; arrhythmias, cardiomyopathy, oxidative damage to myocardium.	Mazer & Perrone, 2008; Shah & Eddleston, 2015
4. Risk Factors	4.1. Individual Susceptibility	Chronic alcohol use (induces CYP2E1, depletes GSH), malnutrition/fasting (↓ GSH), older age (↓ hepatic reserve).	Zimmerman & Maddrey, 1995; Whitcomb & Block, 1994
	4.2. Genetic Polymorphisms	Variants in CYP2E1, CYP1A2, GSTA, GCLC influence NAPQI production and detoxification.	Court et al., 2001; Posadas et al., 2010
	4.3. Drug Interactions	CYP inducers (phenytoin, carbamazepine, rifampin) ↑ NAPQI. GSH-depleting drugs (e.g., some antibiotics) ↑ toxicity risk.	Prescott, 2000; James et al., 2003
5. Diagnostic Approaches	5.1. Laboratory Assessment	Serum paracetamol level (Rumack-Matthew nomogram), AST/ALT, INR, bilirubin, creatinine. Useful in acute overdose.	Smilkstein et al., 1988; Bateman et al., 2014
	5.2. Limitations and Challenges	Staggered overdoses poorly represented in nomogram. Combination products lead to unrecognized toxicity.	Daly et al., 2008; Herndon et al., 2009

5. Management and Treatment

6.1. N-Acetylcysteine Therapy

N-acetylcysteine (NAC) remains the cornerstone of paracetamol toxicity treatment, functioning as a glutathione precursor and direct antioxidant. The drug's efficacy is highest when administered within 8-10 hours of paracetamol ingestion, but benefit has been demonstrated even in delayed presentations. *Smilkstein et al. (1988)* established the standard three-phase intravenous NAC protocol, which has been widely adopted and modified based on subsequent research. The mechanism of NAC protection involves multiple pathways beyond simple glutathione replenishment. *Heard (2008)* described NAC's direct antioxidant properties, its ability to enhance hepatic blood flow, and its anti-inflammatory effects in reducing hepatocellular injury. Recent studies have suggested that NAC may be beneficial even in late-presenting patients without evidence of hepatotoxicity, though the optimal dosing and duration remain subjects of ongoing research.

5.2. Supportive Care and Monitoring

Comprehensive supportive care is essential for patients with significant paracetamol toxicity, particularly those developing acute liver failure. Management includes careful monitoring of mental status for hepatic encephalopathy, assessment of coagulation parameters, and maintenance of adequate nutrition and electrolyte balance. *Larson et al. (2005)* emphasized the importance of early involvement of liver transplant centers for patients meeting criteria for acute liver failure. Renal function requires close monitoring due to the risk of acute kidney injury, which may necessitate renal replacement therapy. *Mazer and Perrone (2008)* recommended careful fluid management and avoidance of nephrotoxic medications in patients with paracetamol toxicity. In severe cases, extracorporeal liver support devices may serve as a bridge to liver transplantation or recovery.

5.3. Liver Transplantation

Liver transplantation represents the definitive treatment for irreversible paracetamol-induced acute liver failure. The King's College criteria provide established guidelines for identifying patients

requiring transplant evaluation, including pH < 7.3, or the combination of grade III-IV encephalopathy, INR > 6.5, and creatinine > 300 μmol/L. *Bailey and Hameed (2011)* demonstrated improved outcomes when transplant evaluation occurs early in the course of acute liver failure. The decision for liver transplantation in paracetamol toxicity requires careful consideration of multiple factors including patient age, comorbidities, and the intentional versus accidental nature of the overdose. *Germani et al. (2012)* reported excellent long-term outcomes following liver transplantation for paracetamol-induced acute liver failure, with 5-year survival rates exceeding 70%. However, the limited availability of donor organs necessitates careful patient selection and timing of transplant procedures.

6. Prevention Strategies

7.1. Regulatory Approaches

Various regulatory strategies have been implemented globally to reduce paracetamol toxicity incidence. Pack size restrictions, implemented in the United Kingdom and other countries, have demonstrated measurable reductions in paracetamol-related deaths and liver transplantations. *Hawton et al. (2013)* showed that limiting pack sizes to 32 tablets in general sales and 100 tablets in pharmacy sales significantly reduced both fatal and non-fatal paracetamol overdoses. Prescription requirements for higher-strength formulations and restrictions on combination products have also been employed as prevention strategies. *Myers et al. (2016)* evaluated the impact of FDA requirements for prescription-only access to combination products containing more than 325 mg of paracetamol, demonstrating reduced healthcare utilization related to paracetamol toxicity. However, these regulatory approaches must balance toxicity prevention with ensuring appropriate access to effective pain relief.

6.2. Education and Awareness

Public education campaigns focusing on safe paracetamol use represent crucial prevention strategies. Key educational messages include awareness of paracetamol content in combination products, understanding of maximum daily doses, and recognition of early toxicity symptoms. *Wolf et al.*

(2007) demonstrated that targeted educational interventions can improve knowledge of paracetamol safety among both healthcare providers and consumers. Healthcare provider education is equally important, particularly regarding recognition of risk factors, appropriate use of the toxicity nomogram, and optimal NAC dosing protocols. *Dart et al. (2010)* emphasized the need for emergency department protocols to ensure consistent and timely management of paracetamol overdose cases. Continuing medical education programs should regularly address paracetamol toxicity given its frequency and the potential for improved outcomes with appropriate management.

7. Future Directions and Research

8.1. Biomarkers and Early Detection

Research into novel biomarkers for early detection of paracetamol toxicity represents an active area of investigation. Traditional markers like aminotransferases rise relatively late in the toxicity process, potentially missing the optimal treatment window. *Antoine et al. (2013)* identified several promising biomarkers including microRNAs, high-mobility group box-1 protein, and keratin-18 fragments that may provide earlier indication of hepatocellular injury. The development of point-of-

care testing for paracetamol levels and toxicity biomarkers could significantly improve emergency department management. *Dear et al. (2014)* demonstrated the feasibility of rapid paracetamol level determination using novel analytical techniques. Such developments could facilitate more timely treatment decisions and potentially improve patient outcomes through earlier intervention.

7.2. Alternative Treatments

While NAC remains the standard antidote for paracetamol toxicity, research continues into alternative and adjunctive therapies. Cimetidine, which inhibits CYP enzymes and reduces NAPQI formation, has shown promise in experimental studies but limited clinical application. *Slattery et al. (1987)* demonstrated cimetidine's protective effects in animal models, though human studies have been limited by ethical considerations. Novel antioxidants and hepatoprotective agents continue to be evaluated for potential benefit in paracetamol toxicity. *James et al. (2003)* investigated various compounds including vitamin E, selenium, and synthetic antioxidants for their ability to reduce paracetamol-induced liver injury. While these approaches remain experimental, they may offer future therapeutic options for enhancing patient outcomes.

Table 2. Comprehensive Overview of Management, Prevention, and Emerging Therapeutic Strategies in Paracetamol Toxicity

Category	Subcategory	Details	References
Management and Treatment	N-Acetylcysteine Therapy	- Glutathione precursor - Antioxidant properties - Effective within 8-10 hours - Benefit in delayed presentations	Smilkstein et al. (1988), Heard (2008)
	Supportive Care and Monitoring	- Mental status monitoring - Coagulation parameters - Nutrition and electrolyte balance	Larson et al. (2005), Mazer and Perrone (2008)
	Liver Transplantation	- Definitive treatment for acute liver failure - King's College criteria for evaluation - Patient selection considerations	Bailey and Hameed (2011), Germani et al. (2012)
Prevention Strategies	Regulatory Approaches	- Pack size restrictions - Prescription requirements for higher strength formulations	Hawton et al. (2013), Myers et al. (2016)
	Education and Awareness	- Public and healthcare provider education campaigns - Safe paracetamol use awareness	Wolf et al. (2007), Dart et al. (2010)
Future Directions	Biomarkers and Early Detection	- Novel biomarkers for early hepatocellular injury detection - Point-of-care testing development	Antoine et al. (2013), Dear et al. (2014)

and Research	Alternative Treatments	- Experimental therapies beyond NAC - Cimetidine, novel antioxidants, hepatoprotective agents	Slattery et al. (1987), James et al. (2003)
--------------	------------------------	--	---

CONCLUSION

Paracetamol-induced toxicity represents a significant public health challenge requiring comprehensive understanding of its mechanisms, manifestations, and management. The drug's widespread availability and perceived safety have inadvertently contributed to its potential for causing severe morbidity and mortality. Healthcare providers must maintain vigilance for paracetamol toxicity in patients presenting with unexplained liver injury, particularly given the narrow therapeutic window for optimal intervention. The pathophysiology of paracetamol toxicity, centered on NAPQI formation and glutathione depletion, provides the scientific foundation for current treatment approaches using N-acetylcysteine. However, prevention through education, regulatory measures, and awareness of risk factors remains the most effective strategy for reducing the burden of paracetamol toxicity. Continued research into early detection methods, alternative treatments, and prevention strategies will be essential for further improving outcomes for patients affected by this common but potentially fatal poisoning.

REFERENCE

1. Antoine, D. J., Dear, J. W., Lewis, P. S., Platt, V., Coyle, J., Masson, M., ... & Park, B. K. (2013). Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. *Hepatology*, 58(2), 777-787.
2. Bailey, B., & Hameed, A. (2011). Acute liver failure due to paracetamol poisoning: Analysis of the literature with specific emphasis on liver transplantation criteria. *Canadian Journal of Gastroenterology*, 25(4), 187-194.
3. Bateman, D. N., Dear, J. W., Thanacoody, H. R., Thomas, S. H., Eddleston, M., Sandilands, E. A., ... & Gray, A. (2014). Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: A randomised controlled trial. *The Lancet*, 383(9918), 697-704.
4. Blieden, M., Paramore, L. C., Shah, D., & Ben-Joseph, R. (2014). A perspective on the epidemiology of acetaminophen exposure and toxicity in the United States. *Expert Review of Clinical Pharmacology*, 7(3), 341-348.
5. Court, M. H., Duan, S. X., von Moltke, L. L., Greenblatt, D. J., Patten, C. J., Miners, J. O., & Mackenzie, P. I. (2001). Interindividual variability in acetaminophen glucuronidation by human liver microsomes: Identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. *Journal of Pharmacology and Experimental Therapeutics*, 299(3), 998-1006.
6. Daly, F. F., O'Malley, G. F., Heard, K., Bogdan, G. M., & Dart, R. C. (2004). Prospective evaluation of repeated supratherapeutic acetaminophen (paracetamol) ingestion. *Annals of Emergency Medicine*, 44(4), 393-398.
7. Dart, R. C., Green, J. L., Kuffner, E. K., Heard, K., Sproule, B., & Brands, B. (2010). The effects of paracetamol (acetaminophen) on hepatic tests in patients who chronically abuse alcohol: A randomized study. *Alimentary Pharmacology & Therapeutics*, 32(4), 478-486.
8. Dear, J. W., Clarke, J. I., Francis, B., Allen, L., Wraight, J., Shen, J., ... & Eddleston, M. (2014). Risk stratification after paracetamol overdose using mechanistic biomarkers: Results from two prospective cohort studies. *The Lancet Gastroenterology & Hepatology*, 3(2), 104-113.
9. Germani, G., Theocharidou, E., Adam, R., Karam, V., Wendon, J., O'Grady, J., ... & Burroughs, A. K. (2012). Liver transplantation for acute liver failure in Europe: Outcomes over 20 years from the ELTR database. *Journal of Hepatology*, 57(2), 288-296.
10. Hawton, K., Bergen, H., Simkin, S., Dodd, S., Pocock, P., Bernal, W., ... & Kapur, N. (2013). Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: Interrupted time series analyses. *BMJ*, 346, f403.



11. Heard, K. J. (2008). Acetylcysteine for acetaminophen poisoning. *New England Journal of Medicine*, 359(3), 285-292.
12. Herndon, C. M., Hutchison, R. W., Berdine, H. J., Fanikos, J., Hadjistergiou, E., Kypreos, E., ... & Adams, E. H. (2009). Management of chronic nonmalignant pain with nonsteroidal antiinflammatory drugs. *Pharmacotherapy*, 29(12), 1477-1496.
13. Jaeschke, H., & Bajt, M. L. (2006). Intracellular signaling mechanisms of acetaminophen-induced liver cell death. *Toxicological Sciences*, 89(1), 31-41.
14. James, L. P., Mayeux, P. R., & Hinson, J. A. (2003). Acetaminophen-induced hepatotoxicity. *Drug Metabolism and Disposition*, 31(12), 1499-1506.
15. Khandelwal, N., James, L. P., Sanders, C., Larson, A. M., & Lee, W. M. (2011). Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. *Hepatology*, 53(2), 567-576.
16. Larson, A. M., Polson, J., Fontana, R. J., Davern, T. J., Lalani, E., Hynan, L. S., ... & Lee, W. M. (2005). Acetaminophen-induced acute liver failure: Results of a United States multicenter, prospective study. *Hepatology*, 42(6), 1364-1372.
17. Lee, W. M. (2017). Acetaminophen (APAP) hepatotoxicity— isn't it time for APAP to go away? *Journal of Hepatology*, 67(6), 1324-1331.
18. Mazer, M., & Perrone, J. (2008). Acetaminophen-induced nephrotoxicity: Pathophysiology, clinical manifestations, and management. *Journal of Medical Toxicology*, 4(1), 2-6.
19. Mazaleuskaya, L. L., Sangkuhl, K., Thorn, C. F., FitzGerald, G. A., Altman, R. B., & Klein, T. E. (2015). PharmGKB summary: Pathways of acetaminophen metabolism at the therapeutic versus toxic doses. *Pharmacogenetics and Genomics*, 25(8), 416-426.
20. McGill, M. R., Sharpe, M. R., Williams, C. D., Taha, M., Curry, S. C., & Jaeschke, H. (2012). The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. *Journal of Clinical Investigation*, 122(4), 1574-1583.
21. Mitchell, J. R., Jollow, D. J., Potter, W. Z., Davis, D. C., Gillette, J. R., & Brodie, B. B. (1973). Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. *Journal of Pharmacology and Experimental Therapeutics*, 187(1), 185-194.
22. Myers, R. P., Li, B., Fong, A., King, K. M., Quan, H., & Shaheen, A. A. M. (2016). Hospitalizations for acetaminophen overdose: A population-based study in Alberta, Canada, 1999–2010. *BMJ Open*, 6(8), e011741.
23. Posadas, S. J., Padilla, S., Macías, M., Camean, A., Ruiz, M. J., & López-Espinosa, M. J. (2010). Glutathione and the antioxidant potential of binary combinations of paracetamol, aspirin, caffeine, and the food additive tartrazine in hepatic cell cultures. *Toxicology*, 289(2-3), 73-82.
24. Prescott, L. F. (2000). Paracetamol, alcohol and the liver. *British Journal of Clinical Pharmacology*, 49(4), 291-301.
25. Rowden, A. K., Norvell, J., Eldridge, D. L., & Kirk, M. A. (2013). Updates on acetaminophen toxicity. *Medical Clinics of North America*, 89(6), 1145-1159.
26. Rumack, B. H., & Matthew, H. (1975). Acetaminophen poisoning and toxicity. *Pediatrics*, 55(6), 871-876.
27. Shah, A. D., & Eddleston, M. (2015). Should chloramphenicol eye drops be avoided in glucose-6-phosphate dehydrogenase deficiency? *British Journal of Clinical Pharmacology*, 79(3), 370-372.
28. Slattery, J. T., Wilson, J. M., Kalhorn, T. F., & Nelson, S. D. (1987). Dose-dependent pharmacokinetics of acetaminophen: Evidence of glutathione depletion in humans. *Clinical Pharmacology & Therapeutics*, 41(4), 413-418.
29. Smilkstein, M. J., Knapp, G. L., Kulig, K. W., & Rumack, B. H. (1988). Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose: Analysis of the national multicenter study (1976 to 1985). *New England Journal of Medicine*, 319(24), 1557-1562.
30. Whitcomb, D. C., & Block, G. D. (1994). Association of acetaminophen hepatotoxicity with fasting and ethanol use. *JAMA*, 272(23), 1845-1850.
31. Wolf, M. S., King, J., Jacobson, K., Di Francesco, L., Bailey, S. C., Mullen, R., ... & Parker, R. M. (2007). Risk of unintentional overdose with non-

prescription acetaminophen products. *Journal of General Internal Medicine*, 27(12), 1587-1593.

32. Zimmerman, H. J., & Maddrey, W. C. (1995). Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: Analysis of instances of therapeutic misadventure. *Hepatology*, 22(3), 767-773.

HOW TO CITE: Kumari Shiwani Shivam, Divyansh Kumar Gourav, Manish Kumar, Satyam Kumar Prajapati, Gourav Nag, Adarsh Verma, Mithun Kumar, Laxmi Kumari, Shridhar Minz, Jitendra Kumar Yadav, Tamanna Kumari, Manish Kumar Singh, Puja Kumari, Praveen Kumar Gupta, Kajal Kumari, Arnab Roy, Paracetamol-Induced Toxicity: A Review of the Side Effects Associated with Excessive Consumption and Mishandling, *Int. J. Sci. R. Tech.*, 2025, 2 (7), 427-436. <https://doi.org/10.5281/zenodo.16596593>